about
New perspectives in glioblastoma antiangiogenic therapyA critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesOligodendroglioma: pathology, molecular mechanisms and markersTERT promoter mutations in primary and secondary glioblastomas.Targeting SOX2 as a Therapeutic Strategy in GlioblastomaGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationTERT promoter mutations: a novel independent prognostic factor in primary glioblastomasA novel semi-supervised methodology for extracting tumor type-specific MRS sources in human brain dataSurvival in glioblastoma: a review on the impact of treatment modalities.MRI findings and pathological features in early-stage glioblastoma.MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.Recent advances in subtyping tumors of the central nervous system using molecular data.Advances in epigenetic glioblastoma therapy.Prevalence of Neurotropic Viruses in Malignant Glioma and Their Onco-Modulatory Potential.Single vs. combination immunotherapeutic strategies for glioma.Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.A nested case-control study of 277 prediagnostic serum cytokines and glioma.Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma multiforme.The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor gliomaSomatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas.Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H gliomaAssessment and treatment relevance in elderly glioblastoma patients.Brain neoplasms and coagulation-lessons from heterogeneity.Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.Differential expression of ID4 and its association with TP53 mutation, SOX2, SOX4 and OCT-4 expression levels.Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionIs there pseudoprogression in secondary glioblastomas?Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas.Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomasReprogramming of human cancer cells to pluripotency for models of cancer progressionRadiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.A computational model incorporating neural stem cell dynamics reproduces glioma incidence across the lifespan in the human populationMetabolic reprogramming in mutant IDH1 glioma cells.
P2860
Q26746028-79E6C1AC-DF1D-452A-A1FB-945BF4515743Q26849503-160020A9-4F0A-401A-8664-9D774FD5C315Q26862516-4FB04D52-578D-4E31-A796-0ED5A48605FAQ27002448-2F1BCCB3-A3BE-4573-8EC3-3330B0DF5B26Q27852506-C75E3D01-EF03-481C-B080-389ABEFA0D5AQ28079501-F7E7A5EC-9FE1-4F24-8F5B-496FF721A2E5Q28082603-FC244679-6CB2-49DF-A89F-332DB2FBB469Q28383205-5AE4CD50-FC59-436D-BE10-FBA976AFDAC3Q28397245-8C6C1B26-BEC2-49C6-8452-75CAE9C65A63Q30000658-B43D402B-A766-4B32-A2CA-D1E200E8A79BQ30251810-DC16F7E3-EE2B-40AE-BCF5-230651F9C723Q30943758-4CA23145-F4B0-493D-BD33-897BD2B8BD65Q31137181-9C2CE3B2-65E9-4524-8721-1A679527D4E5Q31145092-3B31D152-E0A1-4147-A021-FAE2342D7780Q33567030-39A19E77-E1F3-4221-8695-0F22D54C1546Q33622517-7C933557-DCC4-4776-BE7E-E6C0CD50F7A2Q33746041-E33D49DF-9D0D-4EF8-A849-63F03B4E6276Q33777905-B2A459D2-0D75-4072-83E6-76730BD22690Q33778545-07E01E99-1D19-4964-AC83-8BA427DB8C83Q33786677-0E5BA9BF-3B50-4F38-BD22-AE754A0D5EFDQ33923950-1C34984C-1C1A-41A0-8748-23303AA16C51Q33945781-D4928B84-4A3C-4A1A-AF1E-8A8075D150D2Q34061985-6EE95761-5B68-4A67-A0B5-D0607F4AAFF4Q34083282-E44EF22A-3DB4-4C83-8C43-0410213D96CEQ34227556-404864F9-E38E-48A9-90E1-1F6796264AF2Q34314291-D9E4F022-4CAC-42B4-88C6-7798AEA812EFQ34359650-77DBE8ED-87E8-41A8-AA14-AF22795B7E42Q34463432-E6014B2E-3AE3-4460-A3E2-0DF71FC636ADQ34518462-E06EC0DB-045F-4E78-B1D9-2937EC5579FAQ34684614-ECB87635-5A7B-4A16-9F9A-215CE015A81DQ34783220-528F1603-EFCB-42E2-91FB-5D6E2E480B21Q34948627-C68CC55B-6FD4-44EE-9694-A85897DB3A60Q35059157-7406BAEF-0C02-4772-A134-CA11B7E07D14Q35146128-313E2C19-117E-48B5-8EB4-AF1B4FCE2FC3Q35149628-A03112B1-61D2-4EFB-91FE-0D0AB32DEB6AQ35204836-644D9A37-C09E-42A6-B081-D49F91728B5EQ35204997-89720CE5-EE27-44C0-B900-515363433064Q35306157-F049FECE-17C5-4833-8938-7B82C73A4BA9Q35436721-FB276DEF-C8BB-412A-9122-CBCA34C98AF1Q35566048-DDEB5EAC-E146-43E2-B9CF-BE422C2B161C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The definition of primary and secondary glioblastoma.
@en
type
label
The definition of primary and secondary glioblastoma.
@en
prefLabel
The definition of primary and secondary glioblastoma.
@en
P1476
The definition of primary and secondary glioblastoma.
@en
P2093
Hiroko Ohgaki
Paul Kleihues
P304
P356
10.1158/1078-0432.CCR-12-3002
P407
P577
2012-12-03T00:00:00Z